To recapitulate, the essential purpose of this study was to determine whether all the tested therapeutic strategies, regardless of their inhibitory influence on the clonal expansion of CD4+ Teff cells in the MLNs, have the capability to suppress the pathogenesis of allergic asthma at its later stage by inhibition and/or enhancement of the production by CD4+ and CD8+ T cells of important cytokines promoting (i.e., IL-4 and IL-17) and/or inhibiting (i.e., IL-10 and TGF-β), respectively, the development of allergic asthma. This evidence concerns the gene TGFB1 and allergic asthma.